Company / Operating Cash Flow per Share
Vaxcyte, Inc. Operating Cash Flow per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$4.82
FY2025
5-year range
-$4.82 / -$2.34
FY2021-FY2025
Trend
-29.8%
vs FY2024
Sector context
#194 of 212
Health Care
What the data says
Among 212 Health Care companies, Vaxcyte, Inc. is in the bottom 8% for operating cash flow per share. Operating Cash Flow per Share has declined for 5 consecutive years, from $-1.58 in FY2020 to $-4.82 in FY2025.
Based on SEC 10-K filings.
-4.82 in FY2025.
Declined from $-3.05 to $-4.82 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 212This company -$4.82 Sector average -$14.72
▼
+67.3% above sector average
Key checks
Key Insights
- Vaxcyte, Inc.'s operating cash flow per share has declined for 5 consecutive years.
- In FY2025, operating cash flow per share decreased 29.8% year-over-year.
- Ranks #194 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.82 | -29.8% |
| FY2024 | -$3.71 | -21.5% |
| FY2023 | -$3.05 | -16.2% |
| FY2022 | -$2.63 | -12.5% |
| FY2021 | -$2.34 | -48.1% |
| FY2020 | -$1.58 | +87.3% |
| FY2019 | -$12.42 | -48.0% |
| FY2018 | -$8.39 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026